A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants

Trial Profile

A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Plozalizumab (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 26 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment due to business decision; No Safety or Efficacy Concerns
    • 26 Jul 2016 Status changed from recruiting to discontinued.
    • 19 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top